In the context of precision medicine, controlled drug delivery systems (CDDSs) have become a research focus. The structural integrity of CDDSs is critical for ensuring an acceptable drug release rule; hence, a CDDS must possess appropriate mechanical properties. In this study, a polycaprolactone/5-fluorouracil (PCL/5-Fu) CDDS was fabricated via solvent evaporation, and the effects of the PCL molecular weight and 5-Fu loading rate on the mechanical properties of the CDDS were evaluated. The results of tensile testing, scanning electron microscopy, and substance analysis indicated that when the content of 5-Fu was less than 9.09% in the developed CDDS, 5-Fu was completely compatible with PCL, and no crystal aggregation was induced. In addition, the maximum 5-Fu loading rate required to retain acceptable mechanical properties was 23.08%, and the corresponding tensile strength of the sample was 12.9 MPa. This strength is sufficient to prevent structural failure and instantaneous drug release due to strength reduction during application of the drug delivery system. In-vitro experimental results demonstrated that the PCL/5-Fu CDDS can achieve controlled drug release over 1000 h. These findings provide a basis for establishing a drug release model for the proposed CDDS.

在精准医疗的背景下，受控给药系统（CDDS）已成为研究热点。CDDS 的结构完整性对于确保可接受的药物释放规则至关重要；因此，CDDS 必须具有适当的机械性能。在本研究中，通过溶剂蒸发制备了聚己内酯/5-氟尿嘧啶 (PCL/5-Fu) CDDS，并评估了 PCL 分子量和 5-Fu 加载速率对 CDDS 机械性能的影响。拉伸试验、扫描电镜和物质分析结果表明，当开发的CDDS中5-Fu含量小于9.09%时，5-Fu与PCL完全兼容，不会引起晶体聚集。此外，保持可接受的机械性能所需的最大 5-Fu 加载率为 23.08%，相应的试样拉伸强度为12.9 MPa。该强度足以防止在给药系统应用期间由于强度降低而导致的结构破坏和瞬时药物释放。体外实验结果表明，PCL/5-Fu CDDS 可以实现 1000 小时以上的药物控释。这些发现为为提议的 CDDS 建立药物释放模型提供了基础。